Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tianshui Lei"'
Autor:
Ling Wei, Xingwu Wang, Liyan Lv, Jibing Liu, Huaixin Xing, Yemei Song, Mengyu Xie, Tianshui Lei, Nasha Zhang, Ming Yang
Publikováno v:
Molecular Cancer, Vol 18, Iss 1, Pp 1-11 (2019)
Abstract Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the second most lethal human cancer. A portion of patients with advanced HCC can significantly benefit from treatments with sorafenib, adriamycin, 5-fluorouraci
Externí odkaz:
https://doaj.org/article/0da94bd130d9437394fbc28ef4d3f4f3
Publikováno v:
DNA and Cell Biology. 39:1111-1118
Advanced nonsmall-cell lung cancer (NSCLC) patients with mutated epidermal growth factor receptor (EGFR) can remarkably benefit from target therapy of EGFR-tyrosine kinase inhibitors (TKIs). Howeve...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46643b8d7f889d71ae23e775649bdaaa
https://doi.org/10.1089/dna.2020.5457
https://doi.org/10.1089/dna.2020.5457
Autor:
Yemei Song, Tianshui Lei, Yankang Li, Jinming Yu, Yue Shen, Nasha Zhang, Jiandong Liu, Ming Yang, Mengyu Xie
Publikováno v:
Biochemical pharmacology. 172
Patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer (NSCLC) benefits from EGFR-tyrosine kinase inhibitor (TKI) treatment. However, drug resistance to EGFR-TKIs remains a great challenge. Single nucleotide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89f08119d7320b548c6cada639f148e2
https://pubmed.ncbi.nlm.nih.gov/31866302
https://pubmed.ncbi.nlm.nih.gov/31866302
Autor:
Huaixin Xing, Jibing Liu, Ming Yang, Mengyu Xie, Ling Wei, Tianshui Lei, Nasha Zhang, Yemei Song, Liyan Lv, Xingwu Wang
Publikováno v:
Molecular Cancer
Molecular Cancer, Vol 18, Iss 1, Pp 1-11 (2019)
Molecular Cancer, Vol 18, Iss 1, Pp 1-11 (2019)
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the second most lethal human cancer. A portion of patients with advanced HCC can significantly benefit from treatments with sorafenib, adriamycin, 5-fluorouracil and pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b132b53ee8510071f686a343c89db22
https://pubmed.ncbi.nlm.nih.gov/31651347
https://pubmed.ncbi.nlm.nih.gov/31651347
Publikováno v:
DNA and cell biology. 38(1)
As a crucial oncogene, B cell lymphoma-2 (BCL-2) could promote cancer cell survival by inhibiting apoptosis via suppressing activation of proapoptotic proteins, such as BAX and BAK. There is a functional rs2279115 genetic polymorphism locating in BCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa79f111efa4c416b6819008596f3acc
https://pubmed.ncbi.nlm.nih.gov/30481055
https://pubmed.ncbi.nlm.nih.gov/30481055
Publikováno v:
The Journal of clinical endocrinology and metabolism. 104(7)
CONTEXT Telomere length may contribute to predisposition to papillary thyroid cancer (PTC). OBJECTIVE To test this hypothesis, we examined the association between leukocyte telomere length and PTC risk. DESIGN/SETTING Case-control study in a Chinese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a8aedfc17fd77ebd62cdf2ba8b1e6b7
https://pubmed.ncbi.nlm.nih.gov/30817819
https://pubmed.ncbi.nlm.nih.gov/30817819
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-6 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-6 (2018)
As a chromosome stabilizer, telomeres play an essential part in maintaining the stability and integrity of human genome. Shortened telomeres have been associated with the development of cancers but it is still largely unclear whether leukocyte telome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::578fac637fff2dae0d764242ebf03548
https://doi.org/10.1038/s41598-018-32954-6
https://doi.org/10.1038/s41598-018-32954-6